Preclinical studies in ApoE mice demonstrated that subcutaneous administration of the mAb induces anti-CS IgG1 antibodies, a Th2-associated subclass in mice, targeting lipoprotein retention without eliciting proinflammatory responses, a critical safety feature for atherosclerosis therapy (202). Here, APOE is linked to atherosclerosis.